Top Story

FDA advisory panel recommends approval of edoxaban for prevention of stroke, systemic embolism

October 30, 2014

The FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 9-1 to recommend that edoxaban, a novel oral anticoagulant, be approved for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

However, the panel was split over issues of dosage and renal function. ENGAGE AF–TIMI 48 trial results indicated that edoxaban (Daiichi Sankyo) was more effective in patients with mildly or moderately impaired renal function than in patients with normal renal function.

Worth Building

Question your allocation to deal with recent stock market volatility

October 30, 2014
The summer stock market doldrums have morphed into a high octane volatile zig-zag. So I ask you – what is new? Haven’t we been here before? The trouble is…
In the Journals

Clinicians may not adhere to guidelines for measuring FFR in intermediate stenoses

October 30, 2014
New data suggest that clinicians with low levels of experience measuring fractional flow reserve are less likely to employ that measurement strategy than those with…
More News Headlines »
CME
figure

Controversial Issues and Challenging Cases in the New Frontier of Obesity Online Activity

This activity is supported by an educational grant from Eisai Inc.

Obesity has become a world-wide issue of utmost importance as its incidence and prevalence are associated with dramatic…
More »
Meeting News Coverage Video
figure

Keith C. Ferdinand, MD, highlights recent data on link between CVDs, diabetes drugs

October 30, 2014
BOSTON — At the Cardiometabolic Health Congress, Keith C. Ferdinand, MD, FACC, professor of clinical medicine at…
More »
CME
figure

Lipid Forum II Highlights

This activity is supported by an educational grant from Genentech.

Risk stratification and appropriate therapies for various dyslipidemias remain difficult concepts for practitioners…
More »